Breakthrough Blood Test for Multiple Myeloma Developed by Scientists

Introduction to Multiple Myeloma

Scientists from Toronto and China have made significant advancements in the detection of multiple myeloma, a prevalent form of blood cancer. This cancer ranks as the second most common blood malignancy and accounts for nearly 20% of all blood cancer fatalities.

Multiple myeloma occurs when certain white blood cells begin to proliferate uncontrollably in the bone marrow, which is the red, spongy tissue within bones responsible for blood cell production. The excessive growth of these cells leads to a crowding effect, hindering the production of other vital blood cells. Consequently, patients experience severe symptoms, including bone pain, anemia, and kidney failure, alongside a compromised immune system. This weakened immunity increases their vulnerability to life-threatening infections such as pneumonia.

Challenges in Current Detection Methods

Currently, the detection of clonal circulating plasma cells (CPCs)—the white blood cells associated with multiple myeloma—is limited and often unreliable. Patients frequently undergo painful bone marrow extractions to confirm the presence of cancerous cells, highlighting the need for better testing methods.

Innovative Blood Test Development

Researchers at the University of Toronto, in collaboration with their Chinese counterparts, have created a new blood test that enhances the reliability and ease of detecting multiple myeloma. This innovation is based on the unique characteristics of CPCs, which are larger than most red and white blood cells.

The team, led by Dongfang Youang, designed a specialized microarray structure featuring pillars and spaces arranged in a diamond pattern. This configuration includes holes small enough to catch CPCs while allowing other blood cells to flow through unobstructed. The method successfully captures over 20% of CPCs in actual blood samples and more than 50% of CPCs introduced into a liquid mimicking blood plasma. This high sensitivity allows for the detection of minimal CPC quantities, making it feasible to analyze samples from healthy individuals or patients in remission.

Future Implications and Research Opportunities

The new blood test holds numerous potential applications. Its heightened sensitivity makes it suitable for identifying early signs of cancer or monitoring relapses in patients as CPC levels rise.

Moreover, the microarray structure presents exciting opportunities for research. By reversing the flow of liquid, researchers can extract captured CPCs for further study, enabling investigations into the cellular structure and genetics of multiple myeloma. This research could pave the way for new treatments and strategies to combat this challenging disease.

Conclusion

The collaborative efforts of scientists in Toronto and China have resulted in a promising breakthrough in the detection of multiple myeloma, offering hope for improved diagnosis and research into this common blood cancer.

References

Youang, D. et al (2019). Mechanical segregation and capturing of clonal circulating plasma cells in multiple myeloma using micropillar-integrated microfluidic device. Retrieved 20 November 2019, from https://aip.scitation.org/doi/10.1063/1.5112050

Tiny filters help detect cancerous blood cells. (2019). Retrieved 20 November 2019, from https://www.eurekalert.org/pub_releases/2019-11/aiop-tfh111219.php

Myeloma Canada | What is Multiple Myeloma?. (2019). Retrieved 20 November 2019, from https://myeloma.ca/en/about-multiple-myeloma/what-is-myeloma

Multiple myeloma. (2019). Retrieved 20 November 2019, from https://en.wikipedia.org/wiki/Multiple_myeloma

Image by Michal Jarmoluk from Pixabay